A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

BACKGROUND To explore the role of bevacizumab and a chemotherapy‐free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition of paclitaxel after progression (HA‐HAT) as first‐line treatment for patients with human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer. METHODS In a noncomparative phase 2 trial, patients were randomized between HAT and HA‐HAT. The primary endpoint was the progression‐free rate at 1 year (1‐year PFR). In the HA‐HAT group, progress... Mehr ...